Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III)

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

540

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions

Vaccine ReactionVaccine Adverse Reaction

Interventions

BIOLOGICAL

In-House Recombinant Hepatitis B (Bio Farma) vaccine

3 doses of In-House Recombinant Hepatitis B (Bio Farma) vaccine

BIOLOGICAL

Registered Hepatitis B vaccine recombinant (Engerix-B)

3 doses of Registered Hepatitis B vaccine recombinant (Engerix-B)